In hindsight I would have preferred to see a capital raising on the agenda at the last AGM rather than a loan from the share register heavyweights.
I would not have been opposed to a cap raise of around 300,000 shares at $18-$20, resulting in around five/six million dollars raised, enough in my opinion to advance demonstrations and manufacturing capability, here we are we again, turning our pockets inside out.
Let's face it you have to spend money to make money, If the remaining technical hurdles are resolved this company has the potential to go mega, I would hate to think that we were delayed or held back because of funding constraints.
Just my opinion - not advice.
DYOR
- Forums
- ASX - By Stock
- AKP
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-25
-
- There are more pages in this discussion • 158 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AKP (ASX) to my watchlist
(20min delay)
|
|||||
Last
$6.20 |
Change
0.000(0.00%) |
Mkt cap ! $181.1M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AKP (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online